Pipeline

Ipsen’s R&D activities are focused on the discovery and development of new molecules and on programs for the lifecycle management of products already marketed by the group (new formulations, extension of indications and registration of products in new geographical areas). Updated at April 15, 2017.

Oncology
Preclinical
Phase I
Phase II
Phase III
Submission
-
-
-
-
-
-
3BP-227
Pancreatic Cancer
X
-
-
-
-
OPS201
Neuroendocrine tumors
-
X
-
-
-
CABOMETYX ®
Renal cell carcinoma, first line
(in partnership with Exelixis)
-
-
X
-
-
ONIVYDE®
Small cell lung cancer, second line
(in partnership with Shire)
-
-
X
-
-
ONIVYDE®
Pancreatic cancer, first line
(in partnership with Shire)
-
-
X
-
-
CABOMETYX ®
Hepatocellular carcinoma, second line
(in partnership with Exelixis)
-
-
-
X
-
SOMATULINE ®
Carcinoid syndrome US
-
-
-
X
TELOTRISTAT ETIPRATE
Carcinoid syndrome
(in partnership with Lexicon) EU
-
-
-
-
X
SOMATULINE ®
Gastroenteropancreatic neuroendocrine tumors
(in partnership with Teijin) JAPAN
-
-
-
X
Neurosciences
Preclinical
Phase I
Phase II
Phase III
Submission
-
-
-
-
-
-
NOVEL BOTULINUM TOXIN
X
-
-
-
-
Short acting toxin
Early spasticity
-
X
-
-
-
VSN 16R
Spasticity (run by Canbex)
-
-
X
-
-
DYSPORT®
Neurogenic detrusor overactivity
-
-
-
X
-
DYSPORT®
Pediatric upper limb spasticity
-
-
-
X
-
DYSPORT®SOLUTION
Glabellar lines
-
-
-
X
-
DYSPORT®
Glabellar lines CHINA
-
-
-
X
-
DYSPORT®
Adult lower limb spasticity US&EU
-
-
-
-
X
DYSPORT®
Pediatric lower limb spasticity EU
-
-
-
X
Rare Diseases
Preclinical
Phase I
Phase II
Phase III
Submission
-
-
-
-
-
-
BIM23B065
Cushing disease
X
-
-
-
-
BIM23B065
Acromegaly
-
X
-
-
SOMATULINE®
Prolonged release formulation. Acromegaly
-
-
X
-
-
SOMATULINE®
Acromegaly, CHINA
-
-
-
X
-
Last update 15/04/2017